Revvity, Inc
$16.83B- Market cap
- $14.53B
- Debt
- +$3.22B
- Cash
- −$919.86M
Capital structure 82% equity / 18% debt · EV / Revenue 5.89x · EV / EBITDA 22.12x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $14.53B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: RVTY stock price at premium vs OGN $130.25 current versus $39.59 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OGN's multiple
Implied fair value · at RVTY's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Premium justified
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVTY FY 2025 (ended Dec 28, 2025) · OGN FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 82% equity / 18% debt · EV / Revenue 5.89x · EV / EBITDA 22.12x
Capital structure 29% equity / 71% debt · EV / Revenue 1.88x · EV / EBITDA 9.07x
RVTY carries the larger enterprise value at $16.83B against $11.70B; OGN trades on the lower EV / Revenue multiple (1.88x vs 5.89x); OGN on the lower EV / EBITDA (9.07x vs 22.12x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REVVITY, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Organon & Co. · implied price per share
Bear
-$8.75
Base
-$5.98
Bull
-$1.08
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.44x
11.52x
Net debt / EBITDA
Leverage against operating earnings
3.02x
6.27x
Cash and equivalents
Liquid reserves on the balance sheet
$919.86M
$574.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
RVTY vs A
WATERS CORP /DE/
RVTY vs WAT
BIO-RAD LABORATORIES, INC.
RVTY vs BIO
METTLER TOLEDO INTERNATIONAL INC/
RVTY vs MTD
DANAHER CORP /DE/
RVTY vs DHR
THERMO FISHER SCIENTIFIC INC.
RVTY vs TMO
PFIZER INC
RVTY vs PFE
BRISTOL MYERS SQUIBB CO
RVTY vs BMY
AbbVie Inc.
RVTY vs ABBV
$3.22B
$8.66B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.